|
|
| Click here for links to all Expanded Tables of Contents |
|
EXPANDED TABLE OF CONTENTS VOLUME 6, NUMBER 5 JUNE 2003 |
| TREATMENT HIGHLIGHTS |
| AGE AND RISK OF SCHIZOPHRENIA |
| For susceptible individuals, it is found that the risk for developing schizophrenia increases through at least age 40. |
| BEHAVIORAL AND PHARMACOLOGICAL TREATMENT OF TRICHOTILLOMANIA |
| Behavioral therapy is found to be effective in the treatment of trichotillomania. |
| ESTROGEN PLUS PROGESTIN THERAPY AND DEMENTIA |
| The combination of estrogen plus progestin is found to increase the risk of dementia in postmenopausal women. |
| SUBSTANCE USE DISORDERS, DEPRESSION, AND SUICIDALITY |
| Among patients with substance dependence, the timing of major depression is found to have clinical relevance in the assessment of suicide risk. |
| OF NOTE |
| Personality traits are found to change during adulthood. |
| ETCETERA |
|
Alcohol Involvement in Fatal Motor Vehicle Crashes
Sleep Tips for Children Children Living with Substance-Abusing or Substance-Dependent Parents |
| PSYCHOPHARMACOLOGY NOTE |
| LENGTH OF ANTIPSYCHOTIC TREATMENT FOR PSYCHOTIC DEPRESSION |
| A preliminary study suggests that in a majority of patients with psychotic depression, treatment with antipsychotic medication does not need to continue for more than 4 months. |
| FDA NEWS AND REVIEW |
| Product Safety Information: The Food and Drug Administration (FDA) has issued a statement warning against the use of Paxil (paroxetine) in children and adolescents for the treatment of major depressive disorder.
Product Safety Information: Warning letters have been sent by the Food and Drug Administration (FDA) to 8 firms that are selling products marketed as dietary supplements for use as street drug alternatives. |
| ASSESSMENT |
| Headache Questionnaire |
| RESOURCES |
| Each issue presents descriptions of clinical resources (eg, professional materials, patient handouts) and information on how to receive those materials. |